Lilly's Garraway on his way to Roche as veteran Horning set to exit by year-end

This comes just twpo weeks after Garrway left Eli Lilly. (Roche)

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer and head of global product development at Roche in the fall.  

He will fill the large shoes left by the 10-year Roche-Genentech veteran Sandra Horning, who is retiring on the last day of this decade.

In a very brief release, the Swiss Big Pharma said that Garraway comes on board from the start of October, with the two working at the Big Pharma until December 31, when Horning officially leaves.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Garraway’s name will sound familiar as he was until very recently Eli Lilly’s SVP of oncology R&D, as well as heading up Lilly’s research laboratories novel target research. He will be based in South San Francisco.

RELATED: Eli Lilly cancer chief Levi Garraway replaced by Loxo CEO Josh Bilenker (for now) as Big Pharma rings the changes

He left unexpectedly at the start of the month “to pursue other opportunities” and it turns out it was a pretty big one.

Lilly has been working on cancer drugs and new therapies but with limited success; Roche is one of the largest oncology players on the planet with its older oncology medicines still raking in billions of dollars each year, though it now wants more of a say in the next-gen form of cancer care.

Suggested Articles

Akcea CEO Paula Soteropoulos, Chief Business Officer Sarah Boyce and Chief Operating Officer Jeff Goldberg are bidding the company adieu.

Weeks after getting off a major $110 million series B round, well-funded Passage Bio has grabbed a new C-suite member on top of its cash haul.

The deal gives Clovis the ex-Europe rights to a cancer candidate set to enter the clinic in the second half of next year.